Medicenna Therapeutics (TSE:MDNA) Announces Earnings Results

Medicenna Therapeutics (TSE:MDNA) announced its earnings results on Thursday. The company reported C($0.06) earnings per share (EPS) for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%.

Medicenna Therapeutics Stock Down 1.7%

Medicenna Therapeutics stock traded down C$0.01 during midday trading on Thursday, reaching C$0.59. The stock had a trading volume of 37,330 shares, compared to its average volume of 108,942. The firm’s fifty day simple moving average is C$0.72 and its 200-day simple moving average is C$0.99. Medicenna Therapeutics has a 1-year low of C$0.54 and a 1-year high of C$1.97. The stock has a market capitalization of C$49.22 million, a P/E ratio of -3.93 and a beta of 2.84. The company has a debt-to-equity ratio of 3.30, a quick ratio of 4.65 and a current ratio of 2.68.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.